Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IKTthis companyInhibikase Therapeutics, Inc.	$1.61	-4.18×	1.17×	0×	-1.17×	-8.7%	0.0%	0.0%	0.0%	-27.9%	-30.1%	-13.8%	0×	2.61×	0×	21.7×	0.0%	2	10.89	2	C
AGENAgenus Inc.	$7.55	-923.53×	-0.34×	0.82×	6.84×	-468.1%	29.6%	-18.0%	0.1%	-0.0%	-34.5%	-170.2%	-1.24×	5.34×	-0.37×	0.41×	0.0%	6	-14.32	2	C+
ATOSAtossa Therapeutics, Inc.	$2.14	-2.19×	1.94×	0×	-1×	88.9%	0.0%	0.0%	0.0%	-88.4%	-94.4%	-39.1%	0×	1.19×	0×	5.53×	0.0%	1	-11.86	2	B-
CGTXCognition Therapeutics, Inc.	$0.69	-4.22×	2.87×	0×	-2.67×	-14.9%	0.0%	0.0%	0.0%	-68.5%	-136.9%	-25.0%	0.02×	1.56×	-3,676.85×	3.45×	0.0%	1	-0.97	2	C+
ESLAEstrella Immunopharma, Inc.	$0.46	-4.46×	-5.54×	0×	-4.29×	-94.4%	0.0%	0.0%	0.0%	126.0%	126.0%	-3.1%	0×	0.11×	0×	0.12×	0.0%	2	-52.49	2	C
EXOZeXoZymes, Inc.	$4.21	-10×	26.89×	0×	-9.98×	-96.8%	0.0%	0.0%	0.0%	-269.6%	-203.1%	-7.3%	0.37×	0.2×	0×	2.51×	0.0%	1	-2.59	1	C-
Peer median	—	-4.46×	1.94×	0×	-2.67×	-94.4%	0.0%	0.0%	0.0%	-68.5%	-94.4%	-25.0%	0×	1.19×	0×	2.51×	0.0%	1	-11.86	2	—